AADAC Polyclonal Antibody

Background:
Microsomal arylacetamide deacetylase competes against the activity of cytosolic arylamine N-acetyltransferase, which catalyzes one of the initial biotransformation pathways for arylamine and heterocyclic amine carcinogens. Arylacetamide deacetylation is an important enzyme activity in the metabolic activation of arylamine substrates to ultimate carcinogens. Displays major serine hydrolase activity in liver microsomes. Hydrolyzes also flutamide, which is an antiandrogen drug used for the treatment of prostate cancer that occasionally causes severe hepatotoxicity. Displays cellular triglyceride lipase activity in liver. Increases intracellular fatty acids derived from hydrolysis of newly formed triglyceride stores.

Research Area: Metabolism, Signal Transduction

Synonyms:
AAAD, Aada, Aadac, Arylacetamide deacetylase (esterase), Arylacetamide deacetylase, CES5A1, DAC

Immunogen: Recombinant protein of human AADAC

Swissprot: P22760
Gene Accession: BC032309

Calculated MW: 46 kDa

Purification Method: Affinity purification

Buffer: PBS with 0.05% sodium azide and 50% glycerol, PH7.4

Concentration: 0.2 mg/mL
Dilution: WB 1:500-1:2000, IHC 1:25-1:100

Storage:
Store at -20°C. Avoid freeze / thaw cycles.

Alternative for product with catalog number:
sc-99249